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Abstract
Higher frequencies of pregnancy complications have been reported among women with sickle cell 
disease (SCD) compared with those without SCD; however, past studies are limited by small 
sample size, narrow geographic area, and use of hospital discharge data. We compared the 
prevalence of maternal complications among intrapartum and postpartum women with SCD to 
those without SCD in a large, geographically diverse sample. Data from the 2004–2010 Truven 
Health MarketScan® Multi-State Medicaid databases were used to assess the prevalence of 
maternal complications among intrapartum and postpartum women 15–44 years of age with and 
without SCD whose race was reported as black. The comparison group of women without SCD 
was further divided into those with chronic conditions associated with multi-organ failure and 
those without chronic conditions. Multivariable log-binomial regression models were used to 
calculate adjusted prevalence ratios for outcomes for women with SCD compared with women in 
the two comparison groups. Of the 335,348 black women with a delivery during 2004–2010, 
1,526 had a diagnosis of SCD (0.5 %). Compared with women without SCD who had chronic 
conditions, women with SCD had higher prevalence of deep vein thrombosis, pulmonary 
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embolism, obstetric shock, pneumonia, sepsis, postpartum infection, and transfusions. SCD was 
also positively associated with acute renal failure, cerebrovascular disorder, respiratory distress 
syndrome, eclampsia, postpartum hemorrhage, preterm birth, and ventilation when compared with 
women without SCD and chronic conditions. Overall, women with SCD have increased 
prevalence of pregnancy complications, even when compared with a group of women with similar 
risk for multi-organ failure.
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Introduction
Sickle cell disease (SCD) is an inherited hemoglobinopathy that affects approximately 
80,000–100,000 Americans in the US, with the majority of cases among African Americans 
[1–3]. The primary manifestations of SCD are chronic hemolytic anemia and pain crises due 
to vaso-occlusion [4, 5]. Repeated vaso-occlusive crises can affect multiple organ systems, 
and individuals with SCD have increased risk of stroke, renal dysfunction, pulmonary 
hypertension, retinal disease, and avascular necrosis [3, 5, 6]. In women with SCD, the 
underlying anemia and multi-organ dysfunction can complicate pregnancy, by affecting the 
cardiovascular, renal, hematologic, and respiratory systems [4, 7]. Improvements in medical 
care and treatment for individuals with SCD coupled with advancements in neonatal care 
have contributed to a decline in morbidity and mortality associated with pregnancy among 
those with SCD; however, the physiological changes in pregnancy still carry important 
clinical risk for some patients with SCD [8].
While most studies of SCD and pregnancy outcomes are limited by small sample size and 
restricted geographic area, two large, population based studies have assessed a variety of 
maternal and infant outcomes associated with SCD. Barfield et al. conducted a retrospective 
cohort study of women of African descent who resided in Massachusetts with a live birth or 
fetal death recorded during 1998–2006 [9]. The authors reported that women with SCD had 
a higher prevalence of preeclampsia, lung disease, and heart disease during the antenatal, 
delivery or postpartum periods compared with women without hemoglobinopathies. In 
addition, the odds of fetal death, preterm birth, low birth weight, and cesarean delivery were 
higher for women with SCD compared with women with no reported hemoglobinopathies 
after adjusting for maternal age, education, parity, plurality, insurance status at delivery, 
prenatal care utilization, smoking and infant gender. Using a nationally representative 
sample of pregnancy-related discharges during 2000–2003, Villers et al. assessed 
pregnancy-related complications and comorbidities for deliveries with and without a SCD 
diagnosis. Compared with deliveries without a SCD diagnosis, those with SCD were more 
likely to have cerebral vein thrombosis, deep vein thrombosis, pneumonia, sepsis, cesarean 
delivery, preterm labor, and fetal growth restriction [10]. These studies provide important 
information on perinatal outcomes for women with SCD; however, the former study 
included women from only one state and the latter study could not assess the influence of 
multiple hospitalizations by the same woman during the study period on the results of the 
Boulet et al. Page 2
Matern Child Health J. Author manuscript; available in PMC 2015 April 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
study. In addition, neither study included information on complications diagnosed in the 
outpatient setting.
Given the limited literature on perinatal outcomes for women with SCD, and the potential 
impact of additional improvements in modern obstetric care and treatment for SCD, there 
remains a substantial need for additional studies of pregnancy-associated complications and 
outcomes for women with SCD. The primary aim of this study was to use a longitudinally 
linked, multi-state health insurance claims database to assess the prevalence of maternal 
complications during the intrapartum and postpartum periods for a cohort of women with 
and without SCD.
Methods
The data used for this analysis were obtained from the 2004–2010 Truven Health 
MarketScan® Multi-State Medicaid databases, which contain individual level, de-identified 
healthcare claims information from Medicaid enrollees in multiple states [11]. These data 
contain information across the continuum of care (e.g. inpatient admissions, outpatient 
services, and outpatient pharmaceutical claims) as well as data on race, age and gender that 
are collected as part of the monthly enrollment record. Every enrollee is assigned a unique 
identifier that facilitates the tracking of individual patients across all types of claims and 
over multiple years. During 2010, the Multi-State Medicaid database contained information 
on more than 6.4 million enrollees residing in twelve unidentified states.
All women aged 15–44 years with a delivery hospitalization during 2004–2010 were 
included. A delivery hospitalization was defined as any inpatient hospital admission record 
with an International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-
CM) code for a pregnancy-related diagnosis or procedure (V27.x, 650, 669.7, 72.0, 72.1, 
72.21, 72.29, 72.31, 72.39, 72.4, 72.51–72.54, 72.6. 72.71, 72.79, 72.8, 72.9, 73.22, 73.59, 
73.6, 74.0–74.2, 74.4, or 74.99) or a diagnosis-related group (DRG) code for vaginal or 
cesarean delivery (370–375 for DRG version 24 and earlier or 765–782 for DRG version 25 
and later) [12]. Records were excluded if the diagnosis contained codes or procedures for 
hydatidiform mole, ectopic pregnancy, other abnormal products of conception, or abortion 
(ICD-9-CM codes 630, 631, 632, 633.x, 634.x–638.x, 639.x, 69.01, 69.51, 74.91, or 75.0). If 
more than one delivery occurred during the study period, data from the first delivery only 
was used for the analysis. The postpartum period was defined as the first 8 weeks after the 
index delivery hospitalization. In order to allow for 8 weeks of follow up for all women, 
deliveries occurring after October 31, 2010 were excluded from the analysis.
Sickle cell disease was identified by the presence of an ICD-9-CM code for SCD (282.41, 
282.42, or 280.60–282.69) recorded in any position during an inpatient (15 diagnostic fields 
available) or outpatient (2 diagnostic fields available) encounter occurring between 2004 and 
2010. All inpatient SCD diagnoses were considered valid. Diagnoses noted on outpatient 
claims without a corresponding inpatient diagnosis were included only if the diagnosis was 
listed on more than 1 claim at least 30 days apart. The analysis was further restricted to 
women whose race was reported as black due to comparatively low prevalence of SCD in 
US non-black populations [1, 2].
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The comparison group of black women without SCD was categorized into two mutually 
exclusive populations characterized by the presence or absence of selected chronic 
conditions. The chronic conditions were chosen based on their association with multi-organ 
failure, with the assumption that such conditions may present similar risks as SCD for the 
pregnancy outcomes assessed in this study [13]. Thus, by creating a comparison group with 
similarly increased prevalence of organ damage, we could theoretically more effectively 
assess the additional risks for maternal complications that may be due to SCD and not 
attributable to the effects of multi-organ failure. The chronic conditions were identified by 
ICD-9-CM codes and included type 1 diabetes, essential hypertension, pulmonary 
hypertension, congenital heart defects, cardiomyopathy, systemic lupus erythematous, viral 
hepatitis (B and C), epilepsy, and hypothyroidism (see “Appendix”). Because these 
conditions can affect multiple organ systems, we did not group them according to organ 
system. The first comparison group (CC+) was composed of women with any of the selected 
conditions reported during any inpatient or outpatient encounter prior to the delivery 
admission or during the postpartum period. As before, diagnoses based on outpatient claims 
alone were included only if present on more than one claim and the interval between claims 
was ≥30 days. The other comparison group (CC–) was composed of women without any of 
the aforementioned chronic conditions reported in their claims data. Women with other 
types of hemoglobinopathies, including thalassemia (282.49) and unspecified 
hemoglobinopathies (282.7), were excluded from both comparison groups.
ICD-9-CM codes were also used to identify maternal complications that were categorized as 
medical, obstetrical and infectious; these complications and selected procedures (see 
“Appendix”) were included if reported during an emergency room visit, the index 
hospitalization, any postpartum hospitalization, or any outpatient postpartum encounter for 
women with and without SCD. The complications were not mutually exclusive; thus, 
women could have more than one complication reported. Maternal age at delivery was 
derived from the inpatient claim associated with the delivery hospitalization. Plurality (651.x 
or V27.2–V27.7) and smoking (305.1 or 649.0) were ascertained during any inpatient or 
outpatient encounter in the 40 weeks prior to the delivery hospitalization. As before, ≥1 
claim noted ≥30 days apart was required for outpatient diagnoses.
All analyses were conducted using SAS 9.2 (Cary, NC). Two-tailed Chi square tests or t-
tests were used to compare the distribution of maternal characteristics and complications 
among black women with SCD and the two comparison groups of black women without 
SCD. Multivariable log-binomial regression models were used to calculate prevalence ratios 
for maternal complications for women with SCD compared with the CC+ and CC– 
comparison groups, after adjusting for maternal age at delivery, plurality and smoking ≤40 
weeks prior to the delivery hospitalization.
Results
From 2004 to 2010, there were 335,348 Medicaid-enrolled women whose race was reported 
as black and who had a delivery admission; of those, 1,526 (0.5 %) had a diagnosis of SCD. 
Among black women without SCD (n = 333,822), 6.6 % had one or more chronic conditions 
associated with multi-organ failure. Overall, women with SCD tended to be younger than 
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those without SCD, but the difference was more pronounced among those with chronic 
conditions (Table 1). Approximately 3 % of women with SCD had a multiple birth 
compared with about 2 % of women in either comparison group. The prevalence of tobacco 
use was similar between women with SCD and those in the CC+ group (5 %) but was lower 
for women in the CC– group (3.5 %). The mean length of stay during the delivery 
hospitalization of 4.7 days for women with SCD was significantly longer compared with 4.1 
and 2.9 days for women in the CC+ and CC– groups, respectively.
Table 2 depicts the prevalence of maternal complications during the intrapartum and 
postpartum period for women with SCD and those without SCD. Compared with the CC+ 
group, women with SCD had significantly higher frequencies of deep vein thrombosis, 
pulmonary embolism, obstetric shock, eclampsia, and major perineal laceration. With the 
exception of pyelonephritis, the prevalence of all infectious conditions was higher among 
women with SCD than among women in the CC+ group. Approximately 13 % of women 
with SCD had a transfusion during the intrapartum or postpartum period, compared with 2 
% of CC+ women. Women in the CC+ comparison group had a higher prevalence of 
cesarean delivery (48.3 %) than women with SCD (43.3 %) and a lower prevalence of 
operative vaginal delivery (18.5 % vs. 24.0 %). Compared with the CC– group, women with 
SCD had significantly higher prevalence for all outcomes assessed except placental 
abruption, uterine atony, premature rupture of membranes, major perineal laceration and 
obstetric trauma.
With the exception of cesarean delivery, all associations noted in the bivariate analysis 
remained statistically significant after adjusting for maternal age, plurality, and tobacco use. 
For example, women with SCD were at least twice as likely to be diagnosed with deep vein 
thrombosis or pulmonary embolism during the intrapartum or postpartum period compared 
with women in the CC+ group (Table 3). No differences between women with SCD and 
women in the CC+ group were found in the prevalence of acute renal failure, 
cerebrovascular disorder, or respiratory distress. Compared with the CC+ group, women 
with SCD had significantly higher prevalence of obstetric shock (aPR 2.67, 95 % CI 1.71–
4.18) and all infectious complications except pyelonephritis. Women with SCD also had 
lower prevalence of eclampsia (aPR 0.51, 95 % CI 0.45–0.59) and higher prevalence of 
transfusion (aPR 5.21, 95 % CI 4.43–6.12) and operative vaginal delivery (aPR 1.45 95 % 
CI 1.34–1.56) than women in the CC+ group.
Compared with women in the CC– group, women with SCD were approximately 8 times 
more likely to have a diagnosis of cerebrovascular disorder, deep vein thrombosis, and 
respiratory distress syndrome, and 10 times more likely to have pulmonary embolism (Table 
3). Having SCD was positively associated with a number of obstetric complications such as 
obstetric shock (aPR 10.18, 95 % CI 6.78–15.30), eclampsia (aPR 2.25, 95 % CI 1.98–2.57), 
postpartum hemorrhage (aPR 1.47, 95 % CI 1.17–1.85), wound complications (aPR 2.25 95 
% CI 1.76–2.89), and preterm birth (aPR 1.34, 95 % CI 1.23–1.45) when compared with the 
CC– group. Women with SCD were 17 times more likely to have pneumonia and 5 times 
more likely to have sepsis than women in the CC– group. The prevalence of ventilation 
procedures (aPR 3.36 95 % CI 2.11–5.33), transfusion procedures (aPR 12.37 95 % CI 
10.84–14.11), cesarean delivery (aPR 1.21, 1.18–1.23), and operative vaginal delivery (aPR 
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1.23, 95 % CI 1.12–1.35) were also higher among women with SCD than their counterparts 
without chronic conditions. Regardless of comparison group, SCD was not significantly 
associated with placental abruption, uterine atony, premature rupture of membranes, and 
obstetric trauma.
Discussion
Using data from a large, multi-state sample of Medicaidenrolled women, we found that 
black women with SCD are more likely to have medical, obstetric, and infectious 
complications during the intrapartum and postpartum period than black women without 
SCD. Furthermore, the prevalence of several adverse maternal outcomes remained elevated 
even when compared with a group of women without SCD but with similar risk for multi-
organ failure. Although other studies have assessed pregnancy complications associated with 
SCD, the present study is novel in at least two respects: first, pregnancy outcomes for US 
women with SCD were compared to those experienced by a group of women likely to be 
comparably affected by multi-organ failure; and second, the study included complications 
diagnosed in both the inpatient and outpatient setting.
Overall, our findings confirm those of previous studies [9, 10, 14] and provide further 
insight into the maternal risks associated with SCD in pregnancy. For example, we found 
that renal failure, lung disease, eclampsia, and preterm birth were more common among 
women with SCD, but only when compared with black women without SCD and without 
chronic conditions. This finding suggests that multi-organ failure associated with SCD may 
explain the elevated risks for these conditions in women with SCD when compared with the 
general population of women without SCD, as documented in previous studies [9, 10]. In 
addition, our finding that black women with SCD have significantly higher prevalence of 
deep vein thrombosis (DVT) and pulmonary embolism (PE), regardless of the comparison 
group, suggests that the association between thromboembolic events and SCD may be 
independent of the processes related to organ damage. Recently, blood transfusion has been 
recognized as a potential risk factor for venous thromboembolism [15] and may explain 
these results, given the high rate of blood transfusions among women with SCD.
Thrombosis has also been identified as an important complication of SCD in pregnancy [10, 
16] and may be attributable to the hypercoagulable state of those with SCD [17]. Consistent 
with other studies of SCD [18] and sickle cell trait [19], we found that the risk ratio for 
pulmonary embolism among women with SCD was higher than the risk ratio for DVT, when 
compared with women without SCD and without chronic conditions. However, when 
compared with the chronic conditions group, women with SCD were approximately twice as 
likely to have either DVT or PE. The preponderance of PE in relation to DVT among 
women with SCD compared with the general population of women without SCD may reflect 
the underlying physiological changes associated with SCD which can be manifested by 
widespread microvascular obstruction leading to interruption of normal perfusion and 
function of organs such as the lungs [8]. However, when compared with women with similar 
risk for organ damage, we found that the risk for DVT and PE was comparable, suggesting 
that the effects of hypercoagulability are not substantially different for the lungs in 
comparison with other regions of the body.
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Similar to previous studies, we also found an increase in the prevalence of nearly all 
infectious complications among women with SCD when compared to their counterparts 
without SCD. This phenomenon is likely due to the reduced humoral immune response 
secondary to functional or surgical asplenism which predisposes people with SCD to 
encapsulated bacterial infections [20]. Interestingly, we did not find a significant difference 
in the prevalence of pyelonephritis among women with SCD when compared with women in 
the CC+ group. This finding may be explained by the renal dysfunction seen in women with 
SCD and in many of the chronic conditions in the comparison group which may result in a 
similarly increased prevalence of pyelonephritis.
The present study was subject to several limitations. First, it is likely that some 
misclassification according to SCD status was present, despite using data from multiple 
years to ascertain SCD diagnoses. Furthermore, we were unable to assess differences in 
maternal complications according to SCD genotype because this information cannot be 
reliably detected using ICD-9-CM codes. Variations in the risk of adverse pregnancy 
outcomes according to SCD genotype have been reported with lower frequencies of 
maternal and fetal complications among women with HbSC disease than women with 
homozygous HbSS [7, 14]. The implication of this limitation is that the prevalence of 
complications for certain subgroups may be overestimated or underestimated.
Next, because ICD-9-CM codes were also used to ascertain chronic conditions and maternal 
outcomes, these indicators may have also been affected by inaccurate coding. While the 
validity of code-based obstetric diagnoses in discharge databases is variable, findings from a 
recent study indicated that specificity for nearly all pregnancy related comorbidities was 98 
% or greater and false negative errors occurred with a higher frequency than false positives 
[21]. Therefore, the associations reported herein may understate or overstate the true 
association.
Also, because the distribution of age for women without SCD who had chronic conditions 
was skewed toward older ages compared with women with SCD, it is possible that the effect 
measures were modified by age when comparing the prevalence of maternal complications 
for these two groups of women. When age was included as an interaction term in the 
adjusted models, no statistically significant evidence of interaction was observed; however, 
small sample size precluded the meaningful interpretation of some models.
Finally, because the data include only those women enrolled in Medicaid, our findings may 
not be representative of privately insured or uninsured women with SCD. Although studies 
have shown that inpatient hospital, outpatient hospital, or emergency department visits did 
not differ significantly between a national sample of privately insured and Medicaid-
enrolled adults after controlling for health status and other factors [22], higher rates of health 
services utilization have been reported for Medicaid-enrolled children with SCD compared 
their privately insured counterparts [23]. We were also unable to identify the states from 
which the Medicaid sample was drawn and, therefore, could not assess the effects of 
regional variations in the management and treatment of SCD or pregnancy.
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While advances in obstetric care and the treatment of SCD have contributed to significant 
declines in maternal and perinatal mortality rates, women with SCD continue to have 
increased risk for pregnancy complications compared with those without SCD. Moreover, 
having SCD may confer additional risks for adverse maternal outcomes beyond those 
typically associated with multi-organ failure. Therefore, efforts must be made by both 
clinical and public health providers to improve pregnancy outcome for women with SCD. 
Targeted preconception health interventions such as enhanced screening for chronic disease 
complications, reviewing and updating immunization status, genetic counseling, smoking 
cessation, and optimizing hemoglobin and hematocrit levels prior to pregnancy would 
provide opportunities to improve pregnancy outcomes for women with SCD.
In addition, the National Heart, Lung, and Blood Institute (NHLBI)’s Division of Blood 
Diseases and Resources and the Centers for Disease Control and Prevention’s Division of 
Blood Disorders formed an interagency agreement to improve the ability to identify and 
register— with permission—every person in the United States who has a hemoglobinopathy, 
in an effort to determine where best to focus research and education efforts. The NHLBI is 
also developing guidelines for medical professionals treating people who have SCD. These 
guidelines, in combination with the national registry, will provide better information on how 
to advance the quality of life for those with SCD and thus improve their pregnancy 
outcomes [24].
References
1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell 
disease in the United States: national and state estimates. American Journal of Hematology. 2010; 
85(1):77–78. [PubMed: 20029951] 
2. Hassell KL. Population estimates of sickle cell disease in the U.S. American Journal of Preventive 
Medicine. 2010; 38(4 Suppl):S512–S521. [PubMed: 20331952] 
3. Bonds DR. Three decades of innovation in the management of sickle cell disease: the road to 
understanding the sickle cell disease clinical phenotype. Blood Reviews. 2005; 19(2):99–110. 
[PubMed: 15603913] 
4. Rogers DT, Molokie R. Sickle cell disease in pregnancy. Obstetrics and Gynecology Clinics of 
North America. 2010; 37(2):223–237. [PubMed: 20685550] 
5. Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Practice and 
Research Clinical Obstetrics and Gynaecology. 2012; 26(1):25–36. [PubMed: 22113135] 
6. Steinberg MH. Management of sickle cell disease. New England Journal of Medicine. 1999; 
340(13):1021–1030. [PubMed: 10099145] 
7. Rappaport VJ, Velazquez M, Williams K. Hemoglobinopathies in pregnancy. Obstetrics and 
Gynecology Clinics of North America. 2004; 31(2):287–317. vi. [PubMed: 15200965] 
8. ACOG. Practice bulletin No. 78: Hemoglobinopathies in pregnancy. Obstetrics Gynecology. 2007; 
109(1):229–237. [PubMed: 17197616] 
9. Barfield WD, Barradas DT, Manning SE, Kotelchuck M, Shapiro-Mendoza CK. Sickle cell disease 
and pregnancy outcomes: women of African descent. American Journal of Preventive Medicine. 
2010; 38(4 Suppl):S542–S549. [PubMed: 20331956] 
10. Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease 
in pregnancy. American Journal of Obstetrics and Gynecology. 2008; 199(2):125. [PubMed: 
18533123] 
11. Truven health analytics. Truven Health Market-Scan® Multi-State Medicaid databases. 2004–2010
Boulet et al. Page 8
Matern Child Health J. Author manuscript; available in PMC 2015 April 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
12. Kuklina EV, Whiteman MK, Hillis SD, Jamieson DJ, Meikle SF, Posner SF, et al. An enhanced 
method for identifying obstetric deliveries: implications for estimating maternal morbidity. 
Maternal and Child Health Journal. 2008; 12(4):469–477. [PubMed: 17690963] 
13. Sibai, BH.; Easterling, TR.; Stout, K.; Whitty, JE.; Dom-browski, MP.; Colombo, DF., et al. 
Pregnancy and existing disease. In: Gabbe, SG.; Niebyl, JR.; Simpson, JL., editors. Obstetrics 
normal and problem pregnancies. 5th ed. Philadelphia: Churchill Livingstone; 2007. 2007. p. 
861-1249.
14. Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of 
experience at Grady Memorial Hospital, Atlanta, Georgia. American Journal of Obstetrics and 
Gynecology. 2001; 184(6):1127–1130. [PubMed: 11349177] 
15. Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of 
hospitalization for venous thromboembolism. Circulation. 2012; 125(17):2092–2099. [PubMed: 
22474264] 
16. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy 
and the postpartum period: incidence, risk factors, and mortality. American Journal of Obstetrics 
and Gynecology. 2006; 194(5):1311–1315. [PubMed: 16647915] 
17. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: New approaches to an old problem. 
Hematology American Society of Hematology Education Program. 2007:91–96.
18. Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary 
embolism in hospitalized patients with sickle cell disease. American Journal of Medicine. 2006; 
119(10):897–911. [PubMed: 17000225] 
19. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, et al. Sickle cell trait and the 
risk of venous thromboembolism among blacks. Blood. 2007; 110(3):908–912. [PubMed: 
17409269] 
20. Lopez Revuelta K, Ricard Andres MP. Kidney abnormalities in sickle cell disease. Nefrologia. 
2011; 31(5):591–601. [PubMed: 21959727] 
21. Yasmeen S, Romano PS, Schembri ME, Keyzer JM, Gilbert WM. Accuracy of obstetric diagnoses 
and procedures in hospital discharge data. American Journal of Obstetrics and Gynecology. 2006; 
194(4):992–1001. [PubMed: 16580288] 
22. Ku L. Medical and dental care utilization and expenditures under medicaid and private health 
insurance. Medical care research and review. 2009; 66(4):456–471. [PubMed: 19389727] 
23. Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and 
expenditures for privately and publicly insured children with sickle cell disease in the United 
States. Pediatric Blood & Cancer. 2009; 53(4):642–646. [PubMed: 19492318] 
24. National heart, lung, and blood institute. [Accessed 18 Dec 2012] Sickle cell disease awareness 
and education strategy development workshop report. U.S. Department of Health and Human 
Services, National Insititutes of Health. Available at: http://www.nhlbi.nih.gov/meetings/
workshops/Sickle_Cell_Disease_Workshop.pdf.
Appendix
See Table 4.
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Table 3
Adjusted prevalence ratios for the association between sickle cell disease and maternal complications
Complication No SCD, CC+a No SCD, CC–b
aPRc 95 % CI aPRc 95 % CI
Maternal medical complications
  Acute renal failure 0.64 0.34–1.21 6.42 3.42–12.03
  Cerebrovascular disorder 0.85 0.47–1.52 7.92 4.45–14.06
  Deep vein thrombosis 2.47 1.67–3.62 7.75 5.40–11.12
  Pulmonary embolism 1.96 1.17–3.28 10.27 6.33–16.67
  Adult respiratory distress syndrome 1.15 0.77–1.74 7.95 5.28–11.67
Obstetric complications
  Obstetric shock 2.67 1.71–4.18 10.18 6.78–15.30
  Eclampsia 0.51 0.45–0.59 2.25 1.98–2.57
  Postpartum hemorrhage 1.21 0.95–1.55 1.47 1.17–1.85
  Placental abruption 0.74 0.50–1.09 1.14 0.79–1.66
  Wound complications 0.99 0.76–1.28 2.25 1.76–2.89
  Uterine atony, abnormal labor forces 0.99 0.86–1.14 1.04 0.92–1.19
  Preterm labor/birth 0.99 0.90–1.09 1.34 1.23–1.45
  Premature rupture of membranes 1.02 0.81–1.29 0.96 0.77–1.20
  Major perineal laceration 1.50 1.01–2.22 1.01 0.70–1.47
  Obstetric trauma 1.04 0.79–1.36 0.79 0.61–1.02
Infectious complications
  Postpartum infection 1.47 1.15–1.89 2.22 1.76–2.80
  Endometritis/endomyometritis/metritis 1.46 1.02–2.09 2.17 1.56–3.04
  Chorioamnionitis 1.21 1.01–1.46 1.31 1.10–1.56
  Pneumonia 3.13 1.88–5.21 17.22 10.80–27.44
  Sepsis 2.42 1.52–3.85 5.25 3.45–8.00
  Urinary tract infection 1.23 1.03–1.47 2.09 1.77–2.46
  Genitourinary tract infection 1.33 1.09–1.62 2.36 1.96–2.84
  Pyelonephritis 1.14 0.63–2.07 2.16 1.23–3.81
Intrapartum/postpartum procedures
  Ventilation 0.64 0.40–1.03 3.36 2.11–5.33
  Transfusion 5.21 4.43–6.12 12.37 10.84–14.11
  Cesarean delivery 0.94 0.88–1.00 1.21 1.18–1.23
  Operative vaginal delivery 1.45 1.34–1.56 1.23 1.12–1.35
SCD sickle cell disease, CC chronic conditions (diabetes, pulmonary hypertension, essential hypertension, congenital heart defects, cardio-
myopathy, lupus, viral hepatitis, epilepsy and hypothyroidism)
a
“CC+” denotes women without SCD who had report of a chronic condition any time prior to delivery
b
“CC–” denotes women without report of SCD or a chronic condition
cAdjusted for maternal age, plurality, and tobacco use ≤40 weeks prior to delivery admission
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Table 4
ICD-9-CM codes for chronic conditions and maternal and obstetric complications and procedures
ICD-9-CM codes
Chronic conditions
  Type 1 diabetes mellitus 250.0–250.9
  Essential hypertension 401.0–401.9
  Pulmonary hypertension 416.0–416.9
  Congenital heart defects 745.0–745.9
  Cardiomyopathy (hypertrophic
  obstructive or other primary)
425.1, 425.4
  Systemic lupus erythematosus 710.0
  Viral hepatitis (B and C) 070.2–070.3, 070.41,
  070.44, 070.51, 070.54,
  070.70–070.71
  Epilepsy 345.0–345.9
  Hypothyroidism 244.0–244.9
Maternal medical complications
  Acute renal failure 584, 586, 669.3x
  Cerebrovascular disorder 430, 431, 432, 434, 436,
  437.6, 674.0x, 671.5x
  Deep vein thrombosis 671.3x–671.5x, 671.9x,
  451.1, 451.2, 451.81,
  453.1, 453.2,
  453.40– 453.42, 453.8,
  453.9
  Pulmonary embolism 673.2x, 673.8x, 415.1
  Adult respiratory distress syndrome 518.5, 518.81, 518.82,
  518.84, 799.1
Obstetric complications
  Obstetric shock 669.1x, 998.0, 995.4,
  785.5x
  Preeclampsia/eclampsia 642.4x, 642.5x, 642.6x,
  642.7x
  Postpartum hemorrhage 666.0x–666.3x, 639.1x
  Placental abruption 641.2x
  Wound complications 674.1x–674.3x
  Uterine atony, abnormal labor forces 661.0x–661.9x
  Preterm labor/birth 644.0x–644.1x, 644.2x
  Premature rupture of membranes 658.1x
  Major perineal laceration 664.2x, 664.3x, 664.5x
  Obstetric trauma 662.5x–662.9x
Infectious complications
  Postpartum infection 670.xx, 672.xx
  Endometritis/endomyometritis/metritis 615.0–615.9
  Chorioamnionitis 658.4
  Pneumonia 480–483, 485–486, 487.0
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ICD-9-CM codes
  Sepsis 038.x, 995.91, 995.92,
  659.3x
  Urinary tract infection 599.0
  Genitourinary tract infection 646.6x
  Pyelonephritis 590.0, 590.1, 590.80
Intrapartum/postpartum procedures
  Ventilation 93.90, 96.01–96.05, 96.70,
96.71, 96.72
  Transfusion 99.00–99.09, V58.2
  Cesarean delivery 74.0, 74.1, 74.2, 74.4,
  74.99, 669.7
  Operative vaginal delivery 72.0, 72.1, 72.21, 72.29,
  72.39, 72.4, 72.6, 72.71,
  72.79, 669.5x
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